Abstract

Epithelial ovarian cancer (EOC) is a leading cause of gynecological cancer mortality and is often diagnosed at an advanced stage, resulting in poor survival outcomes. Access to specialized gynecological oncology services has been associated with improved prognosis; however, data on its impact in Indonesia remain limited. This study aimed to evaluate the association between gynecologic oncologist (GO) services and disease-free survival (DFS) in patients with EOC. This retrospective cohort study included 76 patients with EOC who were treated at a national cancer hospital in Jakarta between 2015 and 2018. Patient data were obtained from medical records and followed for three years after the primary treatment. Survival outcomes were analyzed using the Kaplan-Meier curve and Cox proportional hazards model. The overall 3-year DFS rate was 41.6%. Patients treated by GO specialists had a higher DFS rate (54.3%) than those treated in hospitals without GO services (24.5%). Multivariate analysis showed a higher recurrence risk in patients treated without GO services (HR 2.75; 95% CI: 1.32 - 5.74). This study’s findings highlight the potential clinical benefits of facilitating early access to specialized GO care for patients with EOC.

References

1. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019; 69 (4): 280–304. DOI: 10.3322/caac.21559.

2. Hong K, Liu Y, Yin H, et al. Identifying Factors Contributing to Delayed Diagnosis of Ovarian Cancer: A Comprehensive Analysis. Dovepress. 2024; 1463—1473. DOI: 10.2147/IJWH.S473381.

3. Cabasag CJ, Fagan PJ, Ferlay J, et al. Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020. Int J Cancer. 2022; 151 (9): 1535–1541. DOI: 10.1002/ijc.34002.

4. United States Centers for Disease Control and Prevention. Screening for Ovarian Cancer. Atlanta, GA: United States Centers for Disease Control and Prevention; 2024.

5. Temkin SM, Bergstrom J, Samimi G, et al. Ovarian cancer prevention in high-risk women. Clin Obstet Gynecol. 2017; 60 (4): 738–757. DOI: 10.1097/GRF.0000000000000318.

6. Gunbay Emgin I, Demirhan Kayacik A, Ilcioglu K. Ovarian cancer and healthy lifestyle awareness among women of reproductive age. BMC Women’s Health. 2025; 26: 2. DOI: 10.1186/s12905-025-04169-1

7. Farina S, Sabatelli A, Boccia S, et al. Environment, lifestyle, and cancer in women. Int J Gynecol Obstet. 2025; 171 (S1): 138–146. DOI: 10.1002/ijgo.70156.

8. Wulandari RD, Laksono AD, Nantabah ZK, et al. Hospital utilization in Indonesia in 2018: Do urban-rural disparities exist? BMC Health Serv Res. 2022; 22: 491. DOI: 10.1186/s12913-022-07896-5.

9. Mayenga DB, Degu A. An assessment of survival outcomes among ovarian cancer patients at the National and Referral Hospital in Kenya. Cancer Rep Hoboken NJ. 2024; 7 (2): e1986. DOI: 10.1002/cnr2.1986.

10. Bouchard-Fortier G, Gien LT, Sutradhar R, Chan, et al. Impact of care by gynecologic oncologists on primary ovarian cancer survival: A population-based study. Gynecol Oncol. 2022; 164 (3): 522–528. DOI: 10.1016/j.ygyno.2022.01.003.

11. Yuniarti E, Prabandari YS, Kristin E, et al. Rationing for medicines by health care providers in Indonesia National Health Insurance System at hospital setting: A qualitative study. J Pharm Policy Pract. 2019; 12: 7. DOI: 10.1186/s40545-019-0170-5.

12. City of Hope. Why Gynecologic Oncologists Are Critical in Women’s Cancer Care. Duarte, CA: City of Hope; 2024.

13. Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer. Lancet. 2019; 393 (10177): 1240-1253. DOI: 10.1016/S0140-6736(18)32552-2.

14. Kim MS, Lee AJ, Shim SH, et al. Comparison of Outcomes in Bowel Resections by Gynecologic Oncologists Versus General Surgeons During Maximal Cytoreductive Surgery for Advanced Ovarian Cancer: Gynecologic Oncology Research Investigators Collaboration Study (GORILLA-3006). Ann Surg Oncol. 2024; 31 (9): 6040–6047. DOI: 10.1245/s10434-024-15643-9.

15. Bajwa A, Chidebe RCW, Adams T, et al. Challenges and opportunities in ovarian cancer care: A qualitative study of clinician perspectives from 24 low- and middle-income countries. J Cancer Policy. 2025; 44: 100582. DOI: 10.1016/j.jcpo.2025.100582.

16. Escayola C, Torrent JJ, Ferron G, et al. When and Who Should Perform Epithelial Ovarian Cancer Surgery? Int J Gynecol Cancer. 2018; 28 (3): 594–599. DOI: 10.1097/IGC.0000000000001188.

17. Climent MT, Serra A, Llueca M, et al. Surgery in Recurrent Ovarian Cancer: A Meta-Analysis. Cancers. 2023; 15 (13): 3470. DOI: 10.3390/cancers15133470.

18. Querleu D, Planchamp F, Chiva L, et al. European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. Int J Gynecol Cancer. 2017; 27 (7): 1534–1542. DOI: 10.1097/IGC.0000000000001041

19. Berek JS, Renz M, Kehoe S, et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynecol Obstet. 2021; 155 (S1): 61–85. DOI: 10.1002/ijgo.13878.

20. Surveillance, Epidemiology, and End Results Program. Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: Statistics. Bethesda, MD: National Cancer Institute; 2026.

21. Upadhyay A, Garg V, Mathur S, et al. Early-Stage epithelial ovarian cancer: Predictors of survival. Gynecol Oncol Rep. 2022; 44: 101083. DOI: 10.1016/j.gore.2022.101083.

22. Henderson JT, Webber EM, Sawaya GF. Screening for Ovarian Cancer: An Updated Evidence Review for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality (US); 2018.

23. American College of Obstetricians & Gynecologists. Hereditary Breast and Ovarian Cancer Syndrome. Washington, DC: American College of Obstetricians & Gynecologists; 2017.

24. Shao C, Guo H, Chen L, et al. Prognostic factors and clinic-pathologic characteristics of ovarian tumor with different histologic subtypes—a SEER database population study of 41,376 cases. Transl Cancer Res. 2023; 12 (8).

25. Hsieh SF, Lau HY, Wu HH, et al. Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma. Int J Environ Res Public Health. 2019; 16 (4): 637. DOI: 10.3390/ijerph16040637.

26. Sung HK, Ma SH, Choi JY, et al. The Effect of Breastfeeding Duration and Parity on the Risk of Epithelial Ovarian Cancer: A Systematic Review and Meta-analysis. J Prev Med Public Health Yebang Uihakhoe Chi. 2016; 49 (6): 349–366. DOI: 10.3961/jpmph.16.066.

27. Toufakis V, Katuwal S, Pukkala E, et al. Impact of parity on the incidence of ovarian cancer subtypes: A population-based case-control study. Acta Oncol Stockh Swed. 2021; 60 (7): 850–855. DOI: 10.1080/0284186X.2021.1919754.

28. Dewick L, Raut J, Asher V. Chemotherapy improves survival rate in Stage 1 ovarian cancers. European J Gynaecol Oncol. 2018; 39 (1): 49-52. DOI: 10.12892/ejgo3715.2018.

29. Li S, Zhu Z. Chemotherapy is not necessary for early-stage serous and endometrioid ovarian cancer after undergoing comprehensive staging surgery. J Ovarian Res. 2020; 13: 91. DOI: 10.1186/s13048-020-00694-9.

Download

Share

COinS